CBL and MPL was conducted in patients with familial myeloproliferative neoplasms (n=88).
Results. Association analysis revealed no difference in haplotype frequency
between familial and sporadic myeloproliferative neoplasms (P=0.6529). No germline mutations in TET2, CBL or MPL that segregate with the disease phenotype were identified. As we observed variability in somatic mutations in the affected members of a pedigree with myeloproliferative neoplasms, we postulated that familial myeloproliferative neoplasms exhibit increased somatic mutagenesis. Accordingly, we compared the incidence of malignant disorders between sporadic and familial patients. Although the overall incidence of malignant disorders did not differ significantly between familial and sporadic myeloproliferative neoplasms, malignancies were more frequent in familial patients in the age between 50 to 70 years (P=0.0198) when compared to sporadic cases.
Conclusions.
We conclude that the JAK2 GGCC haplotype and germline mutations of TET2, CBL or MPL do not explain familial clustering of myeloproliferative neoplasms. As we observed an increased frequency of malignant disorders in familial patients, we hypothesize that the germline genetic lesions that underlie familial clustering of myeloproliferative neoplasms predispose to somatic mutagenesis that is not restricted to myeloid hematopoietic cells but cause increased overall carcinogenesis.
INTRODUCTION
Myeloproliferative neoplasms (MPN) represent a phenotypically diverse group of chronic myeloid malignancies that are characterized by the presence of clonal hematopoiesis and an excessive production of terminally differentiated myeloid blood cells. The so-called "classic Philadelphia-chromosome negative MPN" encompass three distinct diseases, namely polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). The identification of the V617F mutation of the JAK2 gene (JAK2-V617F) led to an important breakthrough in the understanding of MPN disease pathogenesis (1) (2) (3) (4) . Several studies have shown that the somatic acquisition of JAK2-V617F establishes constitutive activation of JAK-STAT signaling, erythropoietin (EPO) independent growth of erythroid progenitor cells and the MPN phenotype in murine bone marrow transplant models (3, 5, 6) . The JAK2-V617F mutation is present in the majority of PV patients (90-98%), whereas only about 50% of patients with ET and PMF are affected (7) . Further investigations revealed that other oncogene mutations that alter JAK-STAT signaling occur frequently in patients negative for the JAK2-V617F mutation, emphasizing the role of this signaling pathway in the disease pathogenesis of MPN. Mutations and deletions in exon 12 of the JAK2 gene (JAK2-ex12) contribute to PV pathogenesis and occur in about 20% of JAK2-V617F negative PV patients, whereas mutations in the thrombopoietin receptor gene MPL have been identified in 1-5% of ET and PMF patients (8, 9) .
Recent investigations have revealed that somatic acquisition of genetic aberrations
is not the only consequential pathogenetic mechanism, but also inherited genetic factors play a pivotal role in the disease development of MPN. Independent studies have identified a JAK2 haplotype that exhibits an increased risk of acquiring mutations at this locus. Several studies showed a non-random distribution of the JAK2-V617F mutation between the two parental JAK2 alleles and that more than 80% of JAK2-V617F mutations were acquired on this particular JAK2 gene haplotype, which is referred to as the GGCC or 46/1 haplotype (10) (11) (12) . Subsequent association analysis revealed that also JAK2-ex12 mutations occur more frequently on the JAK2 GGCC haplotype (13) . Thus, this sequence variant of the JAK2 gene confers susceptibility to JAK2 mutation-positive MPN. Recent literature shows that the GGCC haplotype predisposes to MPL mutation-positive MPN, although the reported association is significantly weaker than the association between the GGCC haplotype and JAK2 mutations (14) . The mechanisms by which this observed difference in mutability between haplotypes is accomplished remains to be elucidated. As the JAK2 GGCC haplotype has not been evaluated in a large series of familial MPN, we aimed to address this question in a demographically matched familial and sporadic MPN patient population. Being a germline predisposition to acquire JAK2 mutations, the GGCC haplotype has been hypothesized to explain familial clustering of MPN (11, 12) . Although MPN have in most instances a sporadic occurrence, familial clustering has been previously reported (15) (16) (17) . Common mutations involved in the pathogenesis of MPN such as JAK2, MPL and TET2 mutations are not inherited, but somatically acquired also in familial cases (16, 18, 19) . One exception is the MPL-S505N mutation that was found germline in a Japanese pedigree with hereditary thrombocythemia (20) . An inherited mutation of the TET2 gene causing a frame shift and premature stop was recently identified in a patient with PV (21) . Furthermore, germline CBL mutations were reported in patients with juvenile myelomonocytic leukemia (22) , but their role in familial MPN remains to be elucidated. Thus, we aimed to investigate the pathogenetic relevance of mutations of TET2, CBL and MPL genes in familial clustering of MPN.
DESIGN AND METHODS

Patients, blood sampling and DNA isolation
A total of 982 consecutive patients with apparent sporadic MPN that were diagnosed and followed from 1973 to 2010 at the Department of Hematology, Fondazione IRCCS Policlinico San Matteo of Pavia, were interviewed for familial history of MPN.
Among these 982 patients, DNA for molecular evaluation was available from 772 cases (79%), which were thus included into the study. Patients were defined as familial cases if two or more individuals within the same pedigree were affected. Part of these patients has been included into a prior clinical study (17) . Diagnosis of MPN was made in accordance with the criteria in use at the time of the first observation (23) (24) (25) (26) (27) . Blast phase was defined by bone marrow or peripheral blood blast cell count 
JAK2 mutation analysis, SNP genotyping and sequence analysis
Molecular studies were performed in all patients with familial (n=88) and sporadic (n=684) MPN with DNA available. The JAK2-V617F mutation burden was assessed using a quantitative polymerase chain reaction (qPCR)-based allelic discrimination assay, as previously described with the following modifications (29) . All reactions were carried out on a RotorGene 6000TM real-time analyzer on a 100-well Gene Disk (Corbett Life Sciences, Mortlake, NSW, Australia) in a final volume of 12 !l containing 1x Brilliant SYBR Green QPCR master mix (Stratagene, Cedar Creek, TX) and 300 nM of both, forward and reverse primers. Serial dilutions starting at 80 ng/!l and ending at 0.4 ng/!l of both, a wild type (WT) and a fully mutated DNA sample were used to construct standard curves from which the JAK2-WT and V617F quantities were calculated for each sample. Results were expressed as the percentage of V617F alleles among total JAK2 alleles. JAK2-V617F mutation analysis using allele-specific PCR amplification was conducted as previously described (30) . Two tagging SNPs in linkage disequilibrium (rs10974944 and rs12343867) were used in order to determine the JAK2 gene haplotype. Genotyping was performed using commercially available Taqman assays (C__31941696 and C__31941689) according to standard protocols and data were analyzed on the 7900HT Real-Time PCR instrument (Applied Biosystems, Foster City, CA).
Identification of cytogenetic aberrations in 3 familial MPN patients of the same pedigree was carried out by high-resolution SNP genotyping using the GeneChip Detailed description of the statistical methods applied in this study is available online under Supplementary Methods.
RESULTS
Patient characteristics
After interview-based investigation of familial MPN history in 772 patients with apparent sporadic MPN from the same demographic area in Italy, 88 (11%) were Sequence analysis of granulocyte DNA in a total of 88 affected patients with a familial history of MPN (52 pedigrees) revealed 12 cases of a non-synonymous mutation in the TET2 gene. Two of the identified mutations were single base pair deletions or insertions causing a frame shift and 7 patients carried a missense mutation ( Table 2 ). In 3 patients we identified a nonsense mutation resulting in a premature stop-codon, one of which was previously described (19) . To evaluate whether these mutations were somatically acquired or inherited, we subsequently performed sequence analysis of DNA samples from T lymphocytes of these patients.
In 5 cases we could confirm the presence of the same mutation in granulocyte as well as T lymphocyte DNA, whereas 7 mutations were only detectable in the granulocyte sample and thus, were somatically acquired. We identified one patient (MPC08-188) who carried 2 mutations of the TET2 gene. Of the 5 patients with a suspected germline mutation, 2 carried an amino acid substitution of proline with serine at position 1723 (P1723S) and a third patient had a valine to leucine substitution at position 1718 (V1718L), all of which were previously reported as normal variants (Table 2) . Two patients carried a newly identified TET2 mutation (A241V and R1440Q) that was present in both, granulocyte and T lymphocyte DNA.
In order to investigate the segregation of these 2 germline mutations with the MPN phenotype, we investigated whether the other affected member of the pedigree carried the same mutation. Of patient MPC08-188, who harbored an A241V germline mutation as well as a somatic R550X mutation of TET2, there was no DNA of the other affected family member available for molecular analysis. In case of patient 377, the other family member with apparent MPN did not carry any mutation of the TET2 gene, thus excluding segregation of the R1440Q mutation with the disease phenotype. Among all of the 52 Italian MPN pedigrees analyzed, no mutations of the CBL or MPL gene were detected. Taken together, these data imply that mutations of TET2, CBL and MPL do not account for the familial occurrence of MPN.
Genetic heterogeneity of somatic mutations and penetrance in familial MPN
We studied an Australian family with 3 individuals affected by MPN using highresolution SNP genotyping and tested for JAK2 and MPL mutations ( Figure 1A ). Of the 3 affected members, one who was diagnosed with ET was positive for the MPL-W515L mutation (MPD214) and one with a diagnosis of PMF had the JAK2-V617F mutation as well as a 5.7 mega base pair deletion on chromosome 22q (MPD227).
The third evaluated member of this family was diagnosed with PMF and was negative for MPL and JAK2 mutations, but carried deletions on chromosomes 2p, 7q and 15q (MPD219) ( Figure 1A ). All of these molecular defects were somatic (data not shown). Notably, the patient who carried the JAK2-V617F mutation was a heterozygous carrier of the JAK2 GGCC haplotype, whereas the other 2 affected members were both homozygous for the non-risk haplotype ( Figure 1A) . Thus, there is no segregation of the JAK2 GGCC haplotype with the MPN phenotype in this family. Of all familial MPN patients analyzed in this study, 24 (27.3%) did not harbor the GGCC haplotype, 51 (58.0%) were heterozygous and 13 (14.8%) were homozygous carriers of the JAK2 gene risk variant ( Figure 1B, Table 1 ). These data demonstrate that up to one third of patients with familial MPN develop the disease although they do not carry the JAK2 risk haplotype.
In order to further characterize the contribution of the JAK2 GGCC haplotype to the familial occurrence of MPN, we performed penetrance estimation calculations. The penetrance in familial MPN was estimated to be 31-35%, a range caused by variable inclusion of some MPN family members. In comparison, the penetrance of the JAK2 GGCC haplotype was lower by approximately three orders of magnitude (0.02%).
This difference in estimated penetrance serves further evidence that the familial predisposition to develop MPN is much stronger than the one conferred by the JAK2 GGCC haplotype.
Malignancies in familial and sporadic MPN
The pedigree shown in Figure 1A serves evidence that the MPN predisposition is not restricted to somatic mutations of JAK2 only. We hypothesize that individuals with a familial history of MPN carry a germline genetic defect that confers a predisposition to increased somatic mutagenesis rates and results in a higher incidence of malignant disorders. To investigate this hypothesis, we compared the occurrence of In a second statistical model, we compared the incidence of malignancies after MPN diagnosis between familial and sporadic patients. The incidence of malignancies was 11.7 per 1000 person-years in familial cases and 6.0 per 1000 person-years in sporadic MPN, with an IRR of 1.95 (P=0.11). After adjustment for age at MPN diagnosis the IRR remained similar (IRR 1.93), thus excluding an effect of the age at diagnosis on the incidence of malignancies other than MPN. Figure 4 reports the comparative Kaplan-Meier estimation of cancer-free survival in both patient groups.
Subjects with familial MPN seemed to have impaired cancer-free survival when compared to patients with sporadic MPN (logrank test, Z=1.4776; P=0.1395). The observed difference in cancer-free survival was not statistically significant, probably due to the overall limited number of study subjects with a familial history of MPN and a low number of tumor cases in both patient populations (7 of 88 in familial and 24 of 684 in sporadic MPN). Thus, larger patient cohorts are necessary in order to confirm the results of this study. Nevertheless, these data suggest that patients with familial clustering of MPN might harbor a yet unidentified predisposition to develop malignant disorders in general, independent from the JAK2 haplotype.
DISCUSSION
The identification of a common genetic variation that influences mutability at the JAK2 gene locus raised the hypothesis that this inherited disease predisposition might underlie familial clustering of MPN. In order to determine the role of the GGCC haplotype in familial occurrence of MPN, we investigated the JAK2 gene haplotype in the currently largest series of patients with familial history of MPN. Hypothesizing that the JAK2 GGCC haplotype explains familial clustering, we expected to observe a higher frequency of the haplotype in familial than in sporadic cases. Our data demonstrate that although the GGCC haplotype is more frequent in familial MPN than in the control population, the haplotype frequency and the risk of acquiring a mutation in the JAK2 gene do not differ between familial and sporadic cases.
Accordingly, association analysis did not reveal a significant correlation between the JAK2 GGCC haplotype and the acquisition of JAK2-V617F when familial and sporadic cases were compared. About 30% of familial MPN patients do not carry the JAK2 GGCC haplotype. Furthermore, penetrance in familial MPN is about three orders of magnitude higher than penetrance of the JAK2 GGCC haplotype. These data are consistent with previous reports that excluded linkage in the JAK2 gene locus using microsatellite marker analysis in 4 pedigrees with familial PV (15) . Taken all together, these observations further support the hypothesis that the GGCC haplotype confers susceptibility to JAK2 mutation-positive MPN, but does not explain familial clustering. (20, 33) . There is only one case of a germline TET2 mutation in familial MPN described so far (21) . Recent literature reports inherited mutations of the CBL gene in juvenile myelomonocytic leukemia (22) . In order to gain further insights into the role of TET2, CBL and MPL mutations in familial clustering of MPN, we performed sequence analysis of these genes in a unique cohort of 88 patients with familial MPN. In summary, we could not identify mutations of TET2, CBL or MPL in our familial MPN cohort that are inherited and segregate with the disease. Hence, the germline genetic defect underlying familial clustering of MPN yet remains to be identified.
Previous studies in familial MPN report an earlier disease onset and significant telomere shortening in second-generation MPN patients, serving as evidence for disease anticipation in familial MPN (34) . A large-scale study including more than 24,000 first-degree relatives of about 11,000 MPN patients revealed a higher risk of developing MPN in relatives of MPN patients (35) . Furthermore, authors report an increased risk of hematologic malignancies (chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL)) and solid tumors (malignant melanoma and brain cancer) among relatives of patients with MPN (35) . Together with the results of our study, these data support the hypothesis that there is a general inherited predisposition to familial MPN that precedes the acquisition of "phenotype-initiating" mutations such as JAK2-V617F and MPL-W515L. Unlike the JAK2 GGCC haplotype, this germline predisposition seems to promote the acquisition of various genetic defects, as shown in Figure 1A . If so, somatic mutability might not only be restricted to MPN but may manifest as an increase in overall carcinogenesis, as suggested by the data of Landgren et al (35) . To investigate the hypothesis that patients with familial MPN exhibit increased somatic mutability, we evaluated the incidence of malignancies in a unique familial MPN cohort consisting of 52 MPN pedigrees. We noted a difference in the occurrence of malignant disorders between familial and sporadic MPN patients, particularly in patients in the age of 50 to 70 years at last follow-up. Statistical analysis revealed that patients with a familial history of MPN have an up to 3-fold increased risk of developing other malignancies.
Furthermore, we noted a difference in cancer types and frequencies that occur in familial and sporadic MPN. Whereas tumors of the gastro-intestinal tract (17%) and skin (10%) were frequent in sporadic MPN, we did not identify any such case among familial MPN patients. Conversely, CLL (10%) and tumors of the brain (10%) were exclusively found in familial MPN patients and NHL were much more frequent in familial (20%) than in sporadic (2%) cases. Kaplan-Meier estimates of cancer-free survival in familial and sporadic MPN patients suggested a decreased cancer-free survival in familial cases, however the difference was not statistically significant. This might be due to the fact that despite being one of the largest familial MPN cohorts, the number of study subjects was limited and the overall incidence of malignant disorders was low in both patients groups.
In accordance with previous studies, our data suggest a higher risk for malignant disorders in patients with familial MPN. The number of familial patients available for investigation was limited, due to the fact that familial MPN is a rare disorder.
Nevertheless, larger patient cohorts are needed in order to further characterize inherited disease predispositions and to identify the genetic defect(s) that underlie familial clustering of MPN. Based on the results of this study, we hypothesize that there is a mutation -of e.g. a tumor suppressor gene -that establishes increased somatic mutability and promotes the consecutive acquisition of genetic defects. Yet, it remains unclear why a mutation in a general tumor suppressor gene would preferentially exert an MPN phenotype. However, previous reports in literature demonstrate that certain mutations or deletions of tumor suppressor genes, such as TP53, VHL, APC, BRCA and CDKN2A exhibit specific genotype-phenotype correlations (36) (37) (38) (39) (40) . Previous studies of the JAK2 GGCC haplotype and the existence of familial MPN demonstrate that germline genetic factors influence somatic mutagenesis and cause various cancer phenotypes. The identification of the mutations that cause familial MPN will further advance our understanding of the interplay between germline and somatic mutagenesis.
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TABLES
SUPPLEMENTARY METHODS
Statistical analysis
Statistical analysis of SNP association in familial and sporadic MPN was performed using the R statistical software (version 2.9.2) (1) in conjunction with the SNPassoc package for R (version 1.6-0) (2). Individuals with reactive conditions (n=203) were used as a demographically matched control population. Allelic association for rs10974944 comparing the allele frequencies in familial and sporadic MPN was carried out using the statistical program PLINK (v1.06) (3).
The approximate penetrance in familial MPN was calculated assuming that all affected members have a "causative hypothetical mutation" in heterozygous state (dominant type of inheritance). Based on this assumption, the probability of each healthy member to carry the mutation was calculated (e.g. the healthy child of an affected member has a 0.5 probability of carrying the MPN-causing mutation, a sibling has 0.5 probability as well, etc.) and the number was summed up to an artificial "number of healthy carriers". Then, the number of 
